The FDA approved Guardant Health’s Shield blood test for colon cancer screening, making it likely to be covered by Medicare and private insurers. It is effective at detecting later-stage cancers but not early-stage polyps. A positive result requires follow-up with a colonoscopy. Doctors see potential for increased screening rates, but its impact on reducing mortality remains to be seen.
